Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.63 |
| ▸ | FABP4 | P15090 | 1/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.52 |
| ▸ | STK3 | Q13188 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957645 | 0.99 | TAS2R14 (0.62) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| SCHEMBL10957630 | 0.99 | TAS2R14 (0.62) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| Hydrochloric Acid SCHEMBL11252208 | 0.99 | TAS2R14 (0.62) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| Hydrochloric Acid SCHEMBL11247445 | 0.98 | TAS2R14 (0.60) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| Hydrochloric Acid SCHEMBL11247442 | 0.98 | TAS2R14 (0.60) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| Hydrochloric Acid SCHEMBL11248758 | 0.98 | TAS2R14 (0.60) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| SCHEMBL11345667 | 0.89 | MAPK10 (0.53) | TAS2R14GSK3AGSK3BAURKADYRK3 | |
| SCHEMBL11796595 | 0.88 | GSK3A (0.50) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| SCHEMBL10957634 | 0.88 | AURKA (0.50) | TAS2R14FABP4DHODHHDAC6GSK3A | |
| SCHEMBL11471834 | 0.86 | MPO (0.52) | TAS2R14FABP4DHODHHDAC6GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1747731-A | Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders | ALTANA PHARMA AG (DE) | 2006-03-15 | — | — | CN | claimed |
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2021188296-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2019173482-A1 | 4-AMINOQUINOLINE COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| EP-0079740-B1 | ANTHRANILOYLOXYALKANOATES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-11-13 | — | — | EP | disclosed |
| US-4508902-A | OXIDATION OF 1,2,3,4-TETRAHYDROQUINOLINE-4-ONES | RHONE-POULENC SANTE (FR) | 1985-04-02 | — | — | US | disclosed |
| US-4508731-A | Microbicidal N-(tetrahydro-2-on-fur-3-yl)-N-substituted acetyl-anilines and -naphthylamines | CIBA GEIGY CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
| US-4482561-A | ANALGESICS, ANTIINFLAMMATORY AGENT, ANTICOAGULANT, AND ANTIDEPRESSANT | RECORDATI, S. A., CHEMICAL & PHARMACEUTICAL CO. (CH) | 1984-11-13 | — | — | US | disclosed |
| US-4448773-A | FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1984-05-15 | — | — | US | disclosed |
| US-4412076-A | Preparation of 4-hydroxyquinolines | RHONE-POULENC SANTE (FR) | 1983-10-25 | — | — | US | disclosed |
| EP-0079740-A1 | Anthraniloyloxyalkanoates | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1983-05-25 | — | — | EP | disclosed |
| US-4160828-A | ANTIINFLAMMATORY AND ANTIRHEUMATIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-10 | — | — | US | disclosed |
| US-3944555-A | ANALGESIC, ANTIINFLAMMATORY | ROUSSEL UCLAF (FR) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | XDH, PNPO, PNP | TAS2R14 4485/4885FABP4 1107/4885DHODH 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.